- Home
- GOSS vs FPH Comparison
GOSS vs FPH Comparison
Compare GOSS & FPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- FPH
- Stock Information
- Founded
- GOSS 2015
- FPH 2009
- Country
- GOSS United States
- FPH United States
- Employees
- GOSS N/A
- FPH N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- FPH Real Estate
- Sector
- GOSS Health Care
- FPH Finance
- Exchange
- GOSS Nasdaq
- FPH Nasdaq
- Market Cap
- GOSS 347.8M
- FPH 390.0M
- IPO Year
- GOSS 2019
- FPH 2017
- Fundamental
- Price
- GOSS $2.47
- FPH $5.68
- Analyst Decision
- GOSS Strong Buy
- FPH
- Analyst Count
- GOSS 4
- FPH 0
- Target Price
- GOSS $8.50
- FPH N/A
- AVG Volume (30 Days)
- GOSS 3.1M
- FPH 150.3K
- Earning Date
- GOSS 08-05-2025
- FPH 10-16-2025
- Dividend Yield
- GOSS N/A
- FPH N/A
- EPS Growth
- GOSS N/A
- FPH 46.82
- EPS
- GOSS N/A
- FPH 1.08
- Revenue
- GOSS $40,237,000.00
- FPH $197,429,000.00
- Revenue This Year
- GOSS N/A
- FPH N/A
- Revenue Next Year
- GOSS $30.65
- FPH N/A
- P/E Ratio
- GOSS N/A
- FPH $5.28
- Revenue Growth
- GOSS N/A
- FPH N/A
- 52 Week Low
- GOSS $0.66
- FPH $3.10
- 52 Week High
- GOSS $2.65
- FPH $6.71
- Technical
- Relative Strength Index (RSI)
- GOSS 68.08
- FPH 56.60
- Support Level
- GOSS $2.38
- FPH $5.51
- Resistance Level
- GOSS $2.65
- FPH $5.77
- Average True Range (ATR)
- GOSS 0.15
- FPH 0.14
- MACD
- GOSS 0.03
- FPH 0.04
- Stochastic Oscillator
- GOSS 76.67
- FPH 95.83
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About FPH Five Point Holdings LLC
Five Point Holdings LLC is an owner and developer of mixed-use, master-planned communities in California. It is engaged in developing new communities that, in addition to homesites, include commercial, retail, educational, and recreational elements, as well as civic areas, parks, and open spaces. Its three reportable segments are Valencia, San Francisco, and Great Park. It derives the majority of revenue from the Great Park segment which includes Great Park Neighborhoods being developed adjacent to and around the Orange County Great Park, a metropolitan park under construction in Orange County, California.